Immutep Ltd - ESG Rating & Company Profile powered by AI
If you work at Immutep Ltd and you wish to licence your ESG rating, please get in touch. Detailed ESG analysis of Immutep Ltd are reached by logging in. Other corporations in the rating industry group for Immutep Ltd are shown.
Immutep Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 6.4, social score of 6.4 and governance score of 8.0.
6.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 355 | Xbrane Biopharma AB | 7.0 | High |
| 355 | Xenetic Biosciences Inc | 7.0 | High |
| 387 | Immutep Ltd | 6.9 | High |
| 387 | Advanced Medical Solutions Group PLC | 6.9 | High |
| 387 | Acrux Ltd | 6.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immutep Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immutep Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Immutep Ltd report the average age of the workforce?
Sign up for free to unlockDoes Immutep Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immutep Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immutep Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Immutep Ltd offer flexible work?
Sign up for free to unlockDoes Immutep Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immutep Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immutep Ltd conduct supply chain audits?
Sign up for free to unlockDoes Immutep Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immutep Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immutep Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immutep Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immutep Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immutep Ltd disclose water use targets?
Sign up for free to unlockDoes Immutep Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Immutep Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Immutep Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Immutep Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immutep Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immutep Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Immutep Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immutep Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immutep Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immutep Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immutep Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immutep Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immutep Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Immutep Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immutep Ltd disclose its waste policy?
Sign up for free to unlockDoes Immutep Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Immutep Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immutep Ltd disclose energy use targets?
Sign up for free to unlockDoes Immutep Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immutep Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immutep Ltd
These potential risks are based on the size, segment and geographies of the company.
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.